Want to see JP:4554 full AI Analyst Report?
Top Page
Fuji Pharma Co., Ltd.
(4554)
Select Model
Select Model
Rating:60Neutral
Price Target:
¥1,910.00
▲(2.52% Upside)
Action:Reiterated
Date:08/06/26
The score is primarily supported by solid underlying financial performance (revenue growth and improving free cash flow), but is held back by clear bearish technical trends (price below key moving averages and negative MACD). Valuation is moderate with a supportive dividend yield, providing some offset to the weak momentum.
Positive Factors
Consistent Revenue Growth
Fuji Pharma's ~17% revenue growth reflects sustained product demand and commercial execution in its prescription business. Durable top-line expansion supports reinvestment in R&D and manufacturing scale, underpinning multi-quarter growth prospects independent of short-term market swings.
Negative Factors
Rising Leverage
An increasing debt-to-equity trend raises financial risk and interest obligations, lowering buffer against revenue or margin shocks. Sustained leverage growth can constrain capital allocation, limit strategic flexibility, and amplify downside during cyclical or regulatory headwinds.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent Revenue Growth
Fuji Pharma's ~17% revenue growth reflects sustained product demand and commercial execution in its prescription business. Durable top-line expansion supports reinvestment in R&D and manufacturing scale, underpinning multi-quarter growth prospects independent of short-term market swings.
Read all positive factors
Fuji Pharma Co., Ltd. (4554) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥48.26B
Dividend Yield2.64%
Average Volume (3M)86.41K
Price to Earnings (P/E)15.4
Beta (1Y)0.77
Revenue Growth20.36%
EPS Growth-5.53%
CountryJP
Employees1,760
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)98.82
Shares Outstanding26,541,100
10 Day Avg. Volume111,080
30 Day Avg. Volume86,410
Financial Highlights & Ratios
PEG Ratio-0.24
Price to Book (P/B)0.80
Price to Sales (P/S)0.73
P/FCF Ratio9.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)107.2
Revenue Forecast (FY)¥63.00B
Fuji Pharma Co., Ltd. Business Overview & Revenue Model
Company Description
Fuji Pharma Co., Ltd. is a pharmaceutical company that operates globally, focusing on the complete spectrum of drug development, from initial research and discovery through manufacturing and commercialization. Its comprehensive product line includ...
How the Company Makes Money
Fuji Pharma generates revenue primarily through (1) sales of prescription pharmaceuticals and (2) contract manufacturing services for other pharmaceutical companies. In its prescription drug business, the company earns money by developing and/or o...
Fuji Pharma Co., Ltd. Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
68
Positive
Cash Flow
65
Positive
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 57.30B | 51.68B | 46.14B | 40.89B | 35.43B | 33.99B |
| Gross Profit | 23.21B | 19.29B | 16.51B | 15.37B | 13.62B | 14.13B |
| EBITDA | 11.11B | 8.96B | 7.56B | 6.88B | 6.52B | 5.46B |
| Net Income | 2.43B | 3.00B | 6.15B | 3.44B | 2.70B | 2.43B |
Balance Sheet | ||||||
| Total Assets | 97.94B | 93.63B | 90.58B | 86.40B | 75.97B | 64.26B |
| Cash, Cash Equivalents and Short-Term Investments | 10.89B | 7.25B | 4.58B | 2.32B | 3.55B | 10.20B |
| Total Debt | 29.62B | 30.94B | 29.25B | 28.95B | 24.57B | 18.66B |
| Total Liabilities | 46.57B | 46.72B | 45.01B | 45.22B | 40.17B | 31.58B |
| Stockholders Equity | 51.36B | 46.91B | 45.56B | 41.17B | 35.80B | 32.68B |
Cash Flow | ||||||
| Free Cash Flow | 3.82B | 3.82B | 1.37B | -1.41B | -5.75B | 2.20B |
| Operating Cash Flow | 5.80B | 5.80B | 4.15B | 1.92B | -658.00M | 5.99B |
| Investing Cash Flow | -4.22B | -4.22B | -1.66B | -5.24B | -11.27B | -2.35B |
| Financing Cash Flow | 954.00M | 954.00M | -435.00M | 1.92B | 5.09B | -5.43B |
Fuji Pharma Co., Ltd. Technical Analysis
Negative
1863.00
Price Trends
2009.32
Negative
2152.46
Negative
2025.35
Negative
Market Momentum
-45.12
Negative
43.88
Neutral
69.26
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4554, the sentiment is Negative. The current price of 1863 is below the 20-day moving average (MA) of 1866.10, below the 50-day MA of 2009.32, and below the 200-day MA of 2025.35, indicating a bearish trend. The MACD of -45.12 indicates Negative momentum. The RSI at 43.88 is Neutral, neither overbought nor oversold. The STOCH value of 69.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4554.
Fuji Pharma Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | ¥110.59B | 12.32 | 5.81% | 2.34% | 14.72% | 52.55% | |
67 Neutral | ¥38.02B | 12.25 | ― | 2.75% | 0.01% | 71.34% | |
66 Neutral | ¥56.18B | 12.76 | ― | 2.52% | ― | -7.20% | |
64 Neutral | ¥19.95B | 8.90 | ― | 3.71% | 2.29% | ― | |
60 Neutral | ¥48.26B | 15.43 | 5.06% | 2.56% | 20.36% | -5.53% | |
52 Neutral | ¥58.85B | 29.55 | ― | 4.71% | -4.71% | -78.91% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:4554
Fuji Pharma Co., Ltd.
1,836.00
422.47
29.89%
JP:4534
Mochida Pharmaceutical Co., Ltd.
3,195.00
112.03
3.63%
JP:4538
Fuso Pharmaceutical Industries,Ltd.
2,284.00
187.43
8.94%
JP:4569
KYORIN Pharmaceutical Co.,Ltd.
1,117.00
-400.26
-26.38%
JP:4577
Daito Pharmaceutical Co., Ltd.
1,316.00
75.36
6.07%
JP:4886
ASKA Pharmaceutical Holdings Co., Ltd.
2,118.00
-127.93
-5.70%
Fuji Pharma Co., Ltd. Corporate Events
Fuji Pharma Delivers Strong Nine-Month Growth and Raises Full-Year Sales Outlook
Aug 6, 2026
Fuji Pharma reported strong consolidated results for the nine months ended June 30, 2026, with net sales rising 22.8% year on year to ¥45.38 billion and operating profit climbing 60.2%. Ordinary profit increased 73.5%, while profit attributab...
Fuji Pharma Books ¥3.5 Billion Securities Loss but Keeps Earnings Outlook
May 12, 2026
Fuji Pharma Co., Ltd. reported an impairment loss of 3,519 million yen on available-for-sale securities in the second quarter of the fiscal year ending September 2026, after a sharp decline in the market value of its holdings. The company had alre...
Fuji Pharma Delivers Strong Interim Growth but Sees Net Profit Decline
May 12, 2026
Fuji Pharma reported strong interim results for the six months to March 31, 2026, with net sales climbing 23.3% to ¥29.7 billion and operating profit nearly doubling to ¥4.4 billion, reflecting improved profitability in its core pharmace...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.